RNA Formulation Resources
-
Getting Genomic Medicines Ready For Prime Time
2/5/2024
Explore the benefits of building a manufacturing process early, how research into LNPs in nucleic acid therapeutics will contribute to the development of future drugs, and more.
-
Oligonucleotide Purification And Synthesis
1/27/2026
Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.
-
Insights Into GMP Manufacturing Of RNA-LNP Drug Products
2/29/2024
Explore key considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, and strategic collaborations.
-
Development Of LNP Formulations Using The KNAUER NanoScaler
12/6/2024
Lipid nanoparticles (LNPs) offer a robust solution for nucleic acids. The NanoScaler system optimizes this technology, enabling scalable and reproducible LNP formulations for diverse applications.
-
Tackling Antimicrobial Resistance
5/14/2024
Learn how three companies collaborated to develop a new antibiotic to address the increasing development of antimicrobial resistance (AMR) that threatens the global health landscape.
-
The mRNA-LNP Decisions That Shape In-Vivo CAR-T Translation
10/27/2026
Early mRNA-LNP formulation decisions influence in vivo CAR-T delivery, expression, repeat-dose tolerability, stability, scalability, and manufacturing flexibility, shaping therapeutic performance and downstream development risk.
-
Fit-For-Purpose Lipids Can Accelerate, Scale, And Improve RNA-LNP Drugs
6/22/2023
Emerging biotech companies are investing in novel delivery capabilities to address different modalities' needs and extra-hepatic delivery. Explore steps to accelerate commercial nanomedicine delivery.
-
Towards A Universal LNP Platform For Multiplex Engineering
6/19/2026
Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.
-
The Future Of mRNA: Four Key Focuses For Industry
8/12/2024
Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry.
-
Building Stability Through Integrated Cryopreservation
3/30/2026
Early integration of standardized, GMP-aligned cryopreservation improves consistency, documentation, and scalability in advanced therapy programs as they progress toward regulatory submissions.